News

Nov 10,2020

Aravive to Receive $12 Million Signing Payment, up to an Additional $207 Million in Future Milestone Payments plus Tiered Royalties

read more >>

Nov 10,2020

Immune-Onc Therapeutics to Present Preclinical Data for IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4) in Solid Tumors, at SITC 2020

read more >>

Oct 07,2020

Cytek Biosciences Completes Series D Funding Round

read more >>

Oct 15,2020

Apexigen’s APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

read more >>

Oct 06,2020

C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

read more >>

Oct 01,2020

C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering

read more >>

Sep 24,2020

OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19

read more >>

Sep 23,2020

OncoImmune Launches First-in-human Clinical Trial for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA4 Recycling for Safer and More Effective Immunotherapy

read more >>

Next page